Company Information

Kitov Pharmaceuticals is an innovative biopharmaceutical drug development company. Leveraging deep regulatory and clinical-trial expertise, Kitov’s veteran team of healthcare and business professionals maintains a proven track record in streamlined end-to-end drug development and approval. Kitov’s flagship combination drug, Consensi™, achieved the primary efficacy endpoints for its Phase III and Phase III/IV clinical trials, and was approved by the U.S. FDA for patients suffering from osteoarthritis pain and hypertension. NT-219, which is developed by Kitov's majority-owned subsidiary, TyrNovo Ltd., is a novel patented small molecule designed to overcome cancer drug resistance that is currently in pre-clinical development. By lowering development risk and cost through fast-track regulatory approval of novel late-stage therapeutics, Kitov plans to deliver rapid ROI and long-term potential to investors, while making a meaningful impact on people’s lives.

Price Data
NASDAQKTOV
Recent News
Sep 26, 2018

TEL AVIV, Israel, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Kitov Pharma (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, today announced that Hadas Reuveni, Ph.D., Chief Technology Officer...

Sep 18, 2018

Tel Aviv, Israel, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, today announced that, following a filing by Kitov’s Chairman...

Aug 29, 2018

el Aviv, Israel, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, today provided a corporate update and reported financial results...

More >


print email